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University Rotterdam, Rotterdam, The NetherlandsA B S T R A C TBackground: Previous studies of health policies in Iran have not
focused exclusively on the drug reimbursement process. Objective:
The aim of this study was to describe the entire drug reimbursement
process and the stakeholders, and discuss issues faced by policy-
makers.Methods: Review of documents describing the administrative
rules and directives of stakeholders, supplemented by published
statistics and interviews with experts and policymakers. Results: Iran
has a systematic process for the assessment, appraisal, and judgment
of drug reimbursements. The two most important organizations in
this process are the Food and Drug Organization, which considers
clinical effectiveness, safety, and economic issues, and the Supreme
Council of Health Insurance, which considers various criteria, includ-
ing budget impact and cost-effectiveness. Ultimately, the Iranian
Cabinet approves a drug and recommends its use to all health
insurance organizations. Reimbursed drugs account for about 53.5%
of all available drugs and 77.3% of drug expenditures. Despite itsee front matter Copyright & 2014, International S
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, Iranstrengths, the system faces various issues, including conﬂicting stake-
holder aims, lengthy decision-making duration, limited access to
decision-making details, and rigidity in the assessment process.
Conclusions: The Iranian drug reimbursement system uses
decision-making criteria and a structured approach similar to those
in other countries. Important shortcomings in the system include out-
of-pocket contributions due to lengthy decision making, lack of
transparency, and conﬂicting interests among stakeholders. Iranian
policymakers should consider a number of ways to remedy these
problems, such as case studies of individual drugs and closer exami-
nation of experiences in other countries.
Keywords: drug registry, drug reimbursement, health insurance,
Iran, policymaking.
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Expenditures in Iran on pharmaceuticals (inpatient and outpatient)
accounted for more than 23% of all health care costs incurred by the
Social Security Organization (SSO) in 2011 (SSO, internal annual
reports). Previous studies have shown that the Iranian pharmaceut-
ical sector is complex and that the process of decision making about
drug reimbursement is complicated [1]. Beyhaghi and Basmenji [2]
concluded that the current system suffers from a lack of integration
and clarity, and emphasized the need to implement a more trans-
parent and consistent system. Delgoshaei et al. [3] attempted to
describe major problems in the drug reimbursement process in Iran
and pointed to undeﬁned and unreliable mechanisms, a reliance on
traditional price setting methods, and a disregard for insurer
capacity to actively negotiate prices with suppliers. Other weak-
nesses mentioned by them included insufﬁcient support for the
vulnerable classes (e.g., the retired) and indigent groups and
inadequate measures to promote rational prescribing and dispens-
ing of low-price alternatives at the pharmacy level [3].
A study of the drug reimbursement process in Iran is an
important step to ensuring that the budget is used optimally.Studies to date, however, have not performed a detailed exami-
nation of the drug reimbursement process. The aim of this study
was to describe the decision-making process regarding drug
reimbursement in Iran. This article covers the current reimburse-
ment process relating to drugs in Iran up to the end of July 2012,
and we describe the role of the two main stakeholders (the
Ministry of Health and Medical Education and the Ministry of
Welfare and Social Security) and other important actors and
stakeholders in this process.Methods
Three different methods were used in this study. To investigate
and describe the administrative rules and the directives of stake-
holders involved in the drug reimbursement process, we exam-
ined formal government documents, including the latest laws
enacted by the Iranian parliament, legislative documents, and
published internal regulations of various stakeholders [4,5]. Inter-
views were conducted with three policymakers, and experts in
the Ministry of Welfare and Social Security, the Food and Drugociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ization (MSIO) enabled us to add some details about the reim-
bursement process. Finally, we used periodically released and
publicly available statistics, especially drug sale statistics pub-
lished by the FDO. The numbers and costs of drugs sold by drug
distribution companies to pharmacies are available in these
publications [4], which enabled us to generate an overview of
the current situation in Iran.Results
Health Insurance Systems
Major changes in the Iranian national health insurance system
began in 1994 with the introduction of universal health insurance
[6]. This policy contained a description of the role of each stake-
holder in the health care sector, the ﬁnancing of health insurance
organizations (HIOs), the health services tariff policy, and the
minimum health service package to be adopted by all HIOs. Since
the introduction of this policy, Iran has had four major health
insurers: the SSO, the MSIO, the Armed Forces Health Insurance
Organization (AFHIO), and the Imam Khomeini Relief Foundation
(IKRF) [6].
The SSO, established in 1953, is a nongovernmental organiza-
tion that covers about 43% of the population. The insurees
comprise wage earners and salaried workers, many self-
employed personnel in different businesses, and many civil
servants [7]. SSO provides two kinds of health care schemes:
direct and indirect health care. Direct health care is provided to
SSO beneﬁciaries through 69 hospitals (8550 hospital beds) and
275 clinics [8]. Beneﬁciaries can also receive indirect health care
from other providers, including health centers (privately, govern-
ment-owned, army) and charity organizations. SSO beneﬁciaries
who are referred to direct health care do not have to make any
payments or co-payments (unless they receive indirect health
care) [8]. Besides health care services, the SSO provides other
social services relating to pension payments, disability compen-
sation, and unemployment insurance services. These long-term
services account for two-thirds of annual SSO expenditures.
The MSIO is a governmental organization established in 1994
that insures about 41% of the population, comprising mainly civil
servants, the self-employed, and rural populations. The MSIO
provides only health insurance services and has variable ﬁnanc-
ing. The activities of the MSIO are similar to the indirect health
care provided through the SSO.
The two other HIOs, the AFHIO and the IKRF, respectively,
cover almost 6% and 2.5% of the population. AFHIO beneﬁciaries
include armed forces personnel and their families, while IKRF
beneﬁciaries include people with physical disabilities and people
with economic or social crises that are so severe that they are not
self-sufﬁcient [9]. In addition, there are 30 or so smaller health
ﬁnancing schemes for privileged members of society or large
organizations (e.g., government ministries, municipalities, banks,
and cooperatives), which provide coverage to their employees
and their families [10].
Key points about the Iranian HIOs are as follows:1. Governmental organizations involved in the health care sys-
tem are supervised by different ministries in the government.
The SSO and the MSIO are supervised by the minister of
welfare and social security, the AFHIO is supervised by the
minister of defense, while the IKRF falls under the direct
supervision of the Iranian president.2. The occupation held by the head of household is the most
important factor that determines HIO enrollment, insurance
premiums, and level of commitment of the HIO to reimbursehealth care services. In fact, most people cannot select their
health insurer and insurance premiums are paid monthly by
their employers. Only self-employed people can choose
between the SSO and the MSIO.3. According to some experts, some people may beneﬁt through
coverage by multiple health insurers while others may have
no health insurance coverage at all. The number of people
without any coverage is estimated to be up to 10% of the
population. Although the socioeconomic proportions of non-
insured people have not been investigated, the experts argue
they are mostly young and poor people who are not eligible to
register by the SSO, the MSIO, and the AFHIO and do not need
health care services (because of being young). Moreover, some
rich people would not be insured because they can easily
afford to pay for health care services in the private sector.4. The contents of the minimum beneﬁt package of the four
main health insurers are determined by the Supreme Council
of Health Insurance (SCoHI), and all insurers are obliged to
provide whatever is included in the package. By law, patients
must make co-payments of 10% and 30% of the costs of
inpatient and outpatient services, respectively. Insurers make
direct payments to pharmacies on a monthly basis, and
patients have to pay both co-payments and a dispensing fee.
The dispensing fee (about €0.70 in 2011) is a ﬁxed-rate fee for
labeling and repackaging that is generally paid out of pocket
for every prescription received. In addition to the minimum
beneﬁt package and co-payment rules, organizations can
provide excess services to prevent catastrophic household
health expenditures. They may cover some nonreimbursed
drugs or decrease the patient’s share of ﬁnancial contribution.
The ratios of cost sharing in drug services provided by HIOs for
diseases are given in Table 1. Cancer patients treated with
nonreimbursed drugs receive ﬁnancial support from HIOs
using different approaches. For example, the SSO pays a
limited yearly grant directly to patients. The MSIO compen-
sates patients for the costs of the drug, the maximum amount
being equal to the costs of pharmacologically similar drugs
that are reimbursed. The AFHIO covers all drug costs through
obligatory supplementary insurance. Last, the IKRF covers 50%
of the costs of all nonreimbursed drugs.The Drug Registration Process in Iran
All new drugs (except orphan drugs, with a disease prevalence of
1 or less in 200,000 people) [11] must be registered by the Council
to Consider and Compile Drugs (CCCD) before they can become
available in Iran. This council is part of the FDO, which is
responsible for drug policy, which, in turn, is supervised by the
minister of health and medical education. All CCCD members are
Ministry of Health and Medical Education employees, and most of
them are clinicians or pharmacists. The ﬁrst step in the registra-
tion of any new drug that is produced or imported is the
completion of three to four drug registry forms (Fig. 1). The
applicant (e.g., drug company, group of physicians, and specialist
society) must prepare documents that address the following
items: efﬁcacy, safety and adverse events, comparative efﬁcacy
with similar drugs, approval history, contraindications, warnings,
precautions, monitoring parameters, pharmacokinetics, patient
compliance, and pharmacoeconomic studies [12]. The CCCD,
however, may exclude one or more of these items on the basis
of the kind of drug and the availability of data.
Applications fall into three categories: 1) new molecules, 2)
new dosage forms, and 3) new salts or new doses of any drug if
the base has already been approved by the CCCD. Suppose the
drug erythromycin, with stearate as a salt in its formulation, is
available on the market and approved by the CCCD. If a new
Table 1 – The ﬁnancial contribution of drug reimbursement services by main Iran health insurance
organizations.
Diseases or
indications
DBC* Outpatients Inpatients
SSO SSO
DHC IHC MISO AFHIO† IKRF DHC IHC MISO AFHIO† IKRF
Cancers 14.8 100 85 90 100 100 100 90 90 100 100
Dialysis (all drugs) 100 100 100 100 100 100 100 90 100 100
Hemophilia (all drugs) 3.4 100 100 100 100 100 100 100 90 100 100
Thalassemia (all drugs) 100 100 100 100 100 100 100 90 100 100
Kidney transplant 1.3 100 100 100 100 100 100 100 90 100 100
Other organ transplants
(immunosuppressives)
0.9 100 100‡ 70 100 100 100 100 90 100 100
Multiple sclerosis
(interferon drugs)
9.4 100 90 90 100 100 100 100 90 100 100
Other diseases 70.2 100 70 70 70 70 100 90 90 100 100
AFHIO, Armed Forces Health Insurance Organization; DBC, Drug Budget Contribution; DHC, Direct Health Care scheme at SSO; IHC, Indirect
Health Care scheme at SSO; IKRF, Imam Khomeini Relief Foundation; MISO, Medical Insurance Services Organization; SSO, Social Security
Organization.
* Drug budget contribution percentage based on IHC of SSO annual reports for outpatients February 10, 2011, to February 9, 2012.
† AFHIO provides the basic and supplementary health insurance together.
‡ In addition to immunosuppressives, other necessary drugs based on kind of transplantation also covered by the SSO.
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Fig. 1 – Overview of the drug registration process in Iran.
CCCD, Council to Consider and Compilation Drugs; FDO,
Food and Drug Organization; N, no; Y, yes.
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succinate), it will fall in the third category.
If the application involves a new molecule, consultation will
be sought from the heads of medical and pharmaceutical soci-
eties, national research centers, and medical universities. Appro-
val of the drug by other organizations (such as the Food and Drug
Administration, the European Medicines Agency, and the Ther-
apeutic Goods Administration) and its use in at least ﬁve coun-
tries (including the United States, European Union countries, or
other countries with a gross domestic product similar to Iran’s)
have an important role in the evaluation. Once a drug is
approved, it is given a unique national code and can be distrib-
uted, prescribed, and used throughout the entire country. Patients
using the drug, however, will have to pay 100% of the drug costs
until the drug is added to the reimbursement list.
The Drug Reimbursement Process in Iran
The SCoHI is the organization that deals with drug reimburse-
ment decisions in Iran. The Drug Beneﬁt Package Review Com-
mittee (DBPRC) is part of the SCoHI and is responsible for drug
assessment. All members and stakeholders of the SCoHI have a
representative in this committee. On the basis of Iran’s rules, all
the health services covered by HIOs should complete the reim-
bursement process. The main rule, as previously mentioned, is
universal health insurance and one of the most important parts
of this law is the appointment of the SCoHI as an important
health insurance policy center. The members of this council are
the minister of welfare and social security (who is also the
chairman of the council), minister of health and medical educa-
tion, minister of economic affairs and ﬁnance, vice president on
strategic planning and control, CEO of the SSO, CEO of the MSIO,
CEO of the AFHIO, president of the Islamic Republic of Iran
Medical Council, chief of the IKRF, and two members of the
Iranian Islamic Parliament (Health Commission and Budget
Commission). The process of reimbursement of health services
is described in section 10 of the Iran universal health insurance
for health care law. Fig. 2 shows the roles of the stakeholders in
the assessment of a drug’s eligibility for reimbursement. Only
drugs that have completed the registration process at the FDO
and received a national code can enter the SCoHI process (Fig. 3);otherwise, the application is rejected. Applicants (drug compa-
nies, physicians, physician specialist societies, etc.) must com-
plete a formal application and submit all the necessary
documents. These documents contain information about the
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Fig. 2 – Overview of the drug reimbursement system in Iran (Stakeholders roles map).
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treatment period, a list of alternative drug therapies with an
analysis of their advantages and disadvantages, and documenta-
tion of the clinical and economic aspects of the drug. This
information is categorized into items, each of which contributes
a certain number of points toward the application. The maximum
possible score is 100 points. If the total score based on an initial
evaluation performed by SCoHI’s experts is less than 50 points,
the application is rejected. If the total score is 50 points or more,
however, the application will be sent to all DBPRC members, who
will be asked to provide comments on the new drug, including the
probable effect that it will have on their budget. Once these
comments are received, the DBPRC will start the assessment
process. If a drug application receives more than 80 points and no
signiﬁcant objections from the council, it will be sent to the SCoHI
with a positive vote. The ﬁnal DBPRC decision will also consider
the budget impact for the country as well as cost-effectiveness
results from other countries. If it ﬁnds that rich countries have
concluded that a drug is not cost-effective, then this new drug
will be considered unlikely to be cost-effective in Iran. All docu-
ments are then sent to all stakeholders 2 weeks before a general
meeting is held in which all stakeholders gather to discuss the
application. The documents contain the following information:1. Comparison of effectiveness with other drugs in the Iranian
pharmacopeia that have similar therapeutic effects.2. Estimated effect on the use of other drugs, which can help to
estimate the overall effect of a drug on a health insurer’s budget.3. Cost modeling for one therapeutic course in outpatient care
and comparison with other drugs with the same therapeutic
effects.4. Average monthly increase in sales in the 6-month period
before the reimbursement application.5. Drug price in other countries with a gross domestic product
similar to that of Iran’s.6. Opinions and comments of certain departments of majormedical universities (the choice of the department is based on
the kind of drug).
All stakeholders will have 2 weeks to examine the information,
after which a general meeting will be held. The ﬁrst goal in the
meeting is to reach consensus about whether or not to reimburse
the drug. If consensus is not achieved, the members will vote for or
against reimbursement. A negative reimbursement decision brings
the process to an end because there is no opportunity to reapply for
reimbursement. If the reimbursement decision is positive, however,
a meeting is arranged with the drug company to negotiate the drug
price. If the drug company is able to agree with the DBPRC about the
price, the application for reimbursement will be accepted, otherwise
it will be rejected. Once the price has been set, the DBPRC will
release a document containing the following information:1. Conditions of reimbursement (e.g., which specialists can
prescribe the drug, which indication(s) the drug can be used
for, and location of production [Iran or other country]). For
example, rituximab is reimbursed only if it is prescribed by an
oncologist to treat non-Hodgkin’s lymphoma and will not be
reimbursed for other purposes (e.g., rheumatic disorders).2. Dosage forms under reimbursement.
3. Whether or not HIOs need to set up a patient registry for the
speciﬁc drug.
4. Assessment of reimbursement eligibility by a HIO before a
patient purchases the drug.
The DBPRC will then send the positive results of its decision
with the agreed prices to the chairman of the SCoHI (minister of
welfare and social security), who will then provide a ﬁnal
summary of comments made during a meeting with the SCoHI.
After this process of deliberation is completed, a report with
SCoHI conclusions is sent to the Iranian Cabinet, which makes
the ﬁnal ofﬁcial decision. According to experts, the Cabinet has
never rejected a drug approved by the SCoHI. Following Cabinet
The applicant submit a reimbursement file to SCoHI
Manufacturer or importer of drug
Applicant
DBPRC: preparation of the assessment, preevaluation 
and stakeholders consultation 
Stakeholders: preparation of comments and budget 
impact
DBPRC: Summarized data and assessment
Rejected 
drugs
Accepted drugs
DBPRC: negotiates the price with applicant
ScoHi: Final decision making
Governmental cabinet: Final approval
The drug is added on the imbursement list, 
decision published in the government official 
journal
Y
N
N
Y
Fig. 3 – Overview of the drug reimbursement process in Iran.
DBPRC, Drug Beneﬁt Package Review Committee; SCoHI,
Supreme Council of Health Insurance; N, no; Y, yes.
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decision is published in the government’s ofﬁcial journal.
Patients can receive the drug with different co-payments based
on disease category (Table 1). Once an international nonproprietary
name in a speciﬁc dosage form is added to the reimbursement list,
all brand names with a similar dosage form are also added. HIOs,
however, will be required to reimburse only the lowest price of all
available brands. For instance, assume that three brands of raniti-
dine 300 mg were available on the market with three different prices
(95, 100, and 110 rials). If ranitidine is covered, all three brands are
covered but the health insurer will reimburse only 95 rials (the price
of the cheapest brand) and patients wanting a more expensive
brand will have to pay the extra costs themselves.Overview of the Current Situation
Currently, there are 3530 international nonproprietary name
national codes in Iran’s drug pharmacopeia [13] and 1800 interna-
tional nonproprietary name national codes and 90 raw materials
for some drugs produced by pharmacies are reimbursed [5]. Mostvitamins, nutritional supplements, infertility drugs, and herbal
extracts are not on the reimbursement list. Based on statistics
provided by the FDO [4], over a 1-year period (February 10, 2011, to
February 9, 2012), the expenditures of the drugs found on the
reimbursement list are approximately 77.3% of the total expendi-
tures of all drugs sold to pharmacies by distribution companies.
The rest is paid by patients or supplemental insurance. Because
no reliable report about expenditures of nonreimbursed drugs is
available, we used sales reports to describe the results of the
reimbursement process. The top 20 nonreimbursed drugs (based
on the results of the previous report) are listed in Table 2. This list
of drugs includes both essential and nonessential drugs, where
drugs are considered nonessential if therapeutically equivalent
drugs are already available on the market.
Although sales statistics cannot accurately describe overall
drug use over long periods of time, it can at least help to estimate
the costs of nonreimbursed patient expenses in various groups of
diseases and changes in the use of nonreimbursed drugs. As seen
in Table 2, because the exact date of presentation of application
to the SCoHI is unknown, it is not possible to estimate the mean
duration of the application process. It is known, however, that
some applicants received a decision a couple of years after
submitting their reimbursement application. This delay appears
to be due to the screening of drugs by the SCoHI. Many con-
troversial drugs seem to have been held back by bureaucratic
barriers while less controversial ones easily passed this bureau-
cratic ﬁlter. However, there are 12 drugs with a “No Application”
status, which usually reﬂects a situation in which the applicant is
not entirely conﬁdent about gaining approval from the SCoHI
because of incompatibility properties of its drugs and SCoHI
expectations. In other cases, however, it is likely that some
companies choose not to apply for reimbursement because they
are sure their drugs will sell well in Iran without it.Discussion
Drug reimbursement decision making is an important process in
the health care sector and has an essential role in the efﬁcient
allocation of resources. Moreover, the expansion of health insur-
ance schemes with affordable and comprehensive packages of
basic services is a great aid in achieving health equity. Although
Iran is a developing country with an economy that is trans-
forming into a market-based economy, the Iranian state still
plays a key role in the economy because it owns large public and
quasi-public enterprises, which partially dominate the manufac-
turing and commercial sectors. The Iranian pharmaceutical
market has undergone great growth in comparison with devel-
oping countries and the market is expanding quickly although a
major share went to biotechnology drugs during the period 1977
to 2010 [14]. Therefore, as a middle-income country with total
health expenditure in 2011 of 6% of the gross domestic product
[15], evidence-based decision making and the appropriate use of
available resources are of paramount importance. Although there
is a process now in place to assess whether or not a new drug is
eligible for reimbursement in Iran, previous studies have found
that this process lacks efﬁciency in making quick and sound
reimbursement decisions. This article’s approach was to go one
step further by providing a more comprehensive view of the
current situation, which enabled us to identify both the strengths
and the shortcomings of the review process.
Our study revealed some strengths of the current process. The
drug registration and reimbursement system in Iran basically
uses the same decision-making criteria that are applied in many
other countries, which include efﬁcacy, safety, and economic
considerations. The SCoHI has managed to eliminate some of the
problems arising from a lack of therapeutic guidelines by drawing
Table 2 – The top 20 nonreimbursement drugs based on sales in the period between February 10, 2011, and
February 9, 2012 (€1 E 16000 rials in 2011).
Drug Major
indication
Drug sales of total
nonreimbursement
sales
FDO
approval
date*
What is clear decision from
SCoHI?
% €
Trastuzumab 440 mg vial Certain breast
cancers
3.0 18,269,992 Before 2008 No (4/2010)
Follitropin 75 IU ampule Infertility 2.5 15,233,374 Before 2008 No application
Orlistat 120 mg capsule Obesity 2.4 14,492,096 Before 2008 No application
Ibuprofen 400 mg pearl† Moderate pain 2.3 13,498,195 Before 2011 No application
Pantoprazole 40 mg tablet†
Gastroesophageal
reﬂux
2.2 13,050,840 Before 2008 No (4/2009)
Tamsulosin 0.4 mg capsule
Benign prostatic
hyperplasia
2.2 12,907,345 Before 2008 No (6/2010)
Sildenaﬁl citrate 100 mg tablet
Erectile
dysfunction
1.9 11,239,538 Before 2008 No application
Menotropins 75 IU FSH þ 75 IU LH
ampule
Fertility
disturbances
1.8 10,809,738 Before 2011 No application
Vaccine-inﬂuenza virus killed
Protect against
inﬂuenza virus
1.7 10,437,869 Before 2008 No application
Drospirenone/estradiol 3/0.03 mg
tablet
Hormonal
contraceptive
1.5 8,928,217 Before 2011 No application
Bevastizumab 400 mg/16 ml vial Various cancers,
colorectal, lung,
breast,
glioblastoma
kidney, and
ovarian
1.4 8,303,165 Before 2011 No application
Salbutamol 100 mcg/dose 200 dose
inhaler†
Relief of
bronchospasm
1.3 7,900,956 20/11/2009 No application
Buprenorphine 2 mg sl tablet†
Moderate to
severe chronic
pain
1.3 7,624,896 Before 2005 Under study
Celecoxib 100 mg capsule
Osteoarthritis,
rheumatoid
arthritis, acute
pain
1.2 7,245,080 Before 2000 No (4/2002)
Zoledronic acid 4 mg vial Osteoporosis 1.1 6,707,129 Before 2008
Yes (wait for government
cabinet)
Pantoprazole 20 mg tablet†
Gastroesophageal
reﬂux
1.1 6,565,955 Before 2008 No (4/2009)
Celecoxib 200 mg capsule
Osteoarthritis,
rheumatoid
arthritis, acute
pain
1.0 5,891,905 Before 2000 No (4/2002)
Prospan syrup† Expectorant 0.9 5,678,314 Before 2011
No application (other domestic
products are reimbursed)
Acetaminophen/caffein/ibuprofen
325/40/200 mg capsule†
Moderate pain 0.9 5,566,815 26/09/2011 No application
Tramadol 100 mg tablet
Moderate to
severe pain
0.9 5,431,981 Before 2002 No application
Sum 32.6 195,783,400
Total 100 600,562,577
FDO, Food and Drug Organization; FSH, follicle-stimulating hormone; IU, International Unit; LH, luteinizing hormone; SCoHI, Supreme Council
of Health Insurance; sl, sublingual.
* When the exact dates were not accessible, we looked at the Iran pharmaceutical market and if the drug was accessible in each year, we used
“Before that year” to describe the FDO approval date.
† There are some others dosage forms in Iran reimbursement list.
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drugs based on their indications (see rituximab example above).
The HIOs can provide not only an appropriate ﬁnancialcontribution, especially for high-risk patients, but also extended
universal coverage in Iran. Improved planning in the area of
reimbursement would help to improve this strength even further.
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are important activities in the process of drug reimbursement.
The drug reimbursement process in Iran can be described as a
shared responsibility process because the decision-making proc-
ess is distributed between two ministries with different interests.
The Ministry of Health and Medical Education is expected to
ensure patient access to useful drugs, while the Ministry of
Welfare and Social Security must try to maximize health insur-
ance coverage with a limited budget. The two ministries therefore
have goals that can conﬂict with each other. In addition, the
SCoHI must consider the recommendations of many stakeholders
when making reimbursement decisions. These two factors of
conﬂicting aims and many decision makers may complicate the
goal of independent decision making. This not only might
challenge the societal goals of drug reimbursement but also cause
other problems such as delayed decisions. One consequence of a
prolonged reimbursement process is an increase in out-of-pocket
payments by patients, who will have to pay for a drug until it is
deemed reimbursable. Some HIOs may therefore use supplemen-
tal insurance or decrease other services to help patients needing
expensive nonreimbursed drugs.
One issue in the current system is that periodical reports by
the SCoHI and the FDO are not publicly available. The reasons for
approving or disapproving drug registration and reimbursements,
and the average durations of the registry and reimbursement
processes, are therefore unknown. This can be viewed as evi-
dence of lack of transparency in the process, which could easily
be resolved if information from the SCoHI and the FDO were
published. In addition, the repetition of some activities during the
evaluation process likely means redundancy, inefﬁciency, and
delays in decision making. A good example of this is the require-
ment by the applicant to supply various economic documents to
both the CCCD and the DBPRC.
The drug reimbursement process uses the same approach in
dealing with different applications regarding required docu-
ments, evaluation, and the decision-making process, regardless
of the budget impact and whether or not the drug is essential.
However, modern health technology assessment methods are not
evident in this process. One consequence of these issues is
reduction in process dynamicity and accumulation of different
applications with different degrees of importance in patient
safety. Although standardization of the required documents and
assessment protocol of the applications is a strength of the
reimbursement system in Iran, it does have its limitations. That
is, process dynamicity could be improved by developing different
approaches to assess drugs in different categories on the basis of
their medical and economic characteristics. Policymakers could
then apply a set of criteria to prioritize drug reimbursement
reviews. For example, a drug with great budget-saving potential
might receive a higher priority. In contrast, a drug could be given
a lower priority if another drug (with a similar safety and
effectiveness proﬁle) is already available on the market.
Improvements in the drug reimbursement system cannot
sufﬁciently compensate for the problems that arise when total
drug expenditures are lower than the desired expenditures;
sometimes a greater budget may be the best way to address the
problem. Moreover, it will be difﬁcult to develop a system that can
satisfy all stakeholders. Nevertheless, it is clear that improve-
ments need to be made. If the number of new and expensive
drugs continues to be high, this can lead to delays in decision
making and various problems such as distrust between the public
and policymakers and an increased number and expenditure of
nonreimbursed drugs, which can, in turn, lead to insurance fraud
by patients and physicians.
The sharing of expertise and experience in middle income
countries would be beneﬁcial for HTA developers and policy
makers in these countries [16]. Iran, because of its geopoliticalposition, market size and relative good performance in terms of
health indicators [14,15,17], is an important country for HTA
researchers in the region and the western part of Asia.Conclusions
The Iranian drug reimbursement system is a shared process
between two different ministries and has an important role in
the efﬁcient allocation of resources. Some issues that have been
discussed reduce the functionality of this system. Therefore,
Iranian policymakers need to make changes and reevaluate the
admission process of new drugs to the reimbursement lists under
a new set of guidelines and possibly a more efﬁcient regulatory
body. In this new set of guidelines, one important step to
improving decision making is greater transparency (e.g., by
publishing reimbursement and registry decisions) on details.
More transparency will help to improve other key performance
indicators of new decision-making process such as independ-
ence, timeliness, and dynamicity. Benchmarking studies on the
Iranian drug reimbursement decision-making process versus
other countries’ processes are needed to highlight Iran’s proce-
dural difﬁculties. Other studies, especially case studies, should
evaluate the exact drug reimbursement decision making in Iran.
These studies and the experiences of other countries can serve as
a framework to ﬁnd the best solutions to improve the drug
reimbursement decision-making process.Acknowledgments
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